BR112015030095B1 - Moduladores do receptor de cxcr7 - Google Patents

Moduladores do receptor de cxcr7 Download PDF

Info

Publication number
BR112015030095B1
BR112015030095B1 BR112015030095-2A BR112015030095A BR112015030095B1 BR 112015030095 B1 BR112015030095 B1 BR 112015030095B1 BR 112015030095 A BR112015030095 A BR 112015030095A BR 112015030095 B1 BR112015030095 B1 BR 112015030095B1
Authority
BR
Brazil
Prior art keywords
ethyl
tetrahydro
isoquinolin
acetamide
benzyl
Prior art date
Application number
BR112015030095-2A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112015030095A2 (pt
Inventor
Fretz Heinz
Philippe Guerry
Thierry Kimmerlin
Francois Lehembre
Julien Pothier
Hervé Siendt
Anja Valdenaire
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of BR112015030095A2 publication Critical patent/BR112015030095A2/pt
Publication of BR112015030095B1 publication Critical patent/BR112015030095B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
BR112015030095-2A 2013-05-30 2014-05-28 Moduladores do receptor de cxcr7 BR112015030095B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2013054478 2013-05-30
IBPCT/IB2013/054478 2013-05-30
PCT/IB2014/061774 WO2014191929A1 (en) 2013-05-30 2014-05-28 Cxcr7 receptor modulators

Publications (2)

Publication Number Publication Date
BR112015030095A2 BR112015030095A2 (pt) 2022-07-12
BR112015030095B1 true BR112015030095B1 (pt) 2023-02-28

Family

ID=50943357

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015030095-2A BR112015030095B1 (pt) 2013-05-30 2014-05-28 Moduladores do receptor de cxcr7

Country Status (30)

Country Link
US (1) US9920010B2 (https=)
EP (1) EP3004082B1 (https=)
JP (1) JP6393749B2 (https=)
KR (1) KR102302580B1 (https=)
CN (1) CN105263924B (https=)
AR (1) AR096490A1 (https=)
AU (1) AU2014272718B2 (https=)
BR (1) BR112015030095B1 (https=)
CA (1) CA2912133C (https=)
CL (1) CL2015003470A1 (https=)
CY (1) CY1119537T1 (https=)
DK (1) DK3004082T3 (https=)
EA (1) EA028604B1 (https=)
ES (1) ES2645470T3 (https=)
HR (1) HRP20171597T1 (https=)
HU (1) HUE036649T2 (https=)
IL (1) IL242782B (https=)
LT (1) LT3004082T (https=)
MA (1) MA38679B1 (https=)
MX (1) MX364104B (https=)
MY (1) MY173564A (https=)
NO (1) NO3004082T3 (https=)
PH (1) PH12015502632A1 (https=)
PL (1) PL3004082T3 (https=)
PT (1) PT3004082T (https=)
SG (1) SG11201509057UA (https=)
SI (1) SI3004082T1 (https=)
TW (1) TWI640510B (https=)
UA (1) UA118562C2 (https=)
WO (1) WO2014191929A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091516A1 (es) 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
ES2732437T3 (es) 2014-12-01 2019-11-22 Idorsia Pharmaceuticals Ltd Moduladores del receptor de CXCR7
WO2017070431A1 (en) * 2015-10-23 2017-04-27 James Merritt Use of ccr1 antagonists as a treatment for tumors of the central nervous system
HRP20230313T1 (hr) * 2016-07-28 2023-05-12 Idorsia Pharmaceuticals Ltd Modulatori receptora cxcr7 piperidina
EA201992676A1 (ru) 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд Фенильные производные в качестве модуляторов pge2 рецепторов
PL3625228T3 (pl) 2017-05-18 2021-12-20 Idorsia Pharmaceuticals Ltd Pochodne pirymidyny jako modulatory receptora pge2
KR102502046B1 (ko) 2018-01-26 2023-02-20 이도르시아 파마슈티컬스 리미티드 Cxcr7 수용체 작동제 (3s,4s)-1-시클로프로필메틸-4-{[5-(2,4-디플루오로-페닐)-이속사졸-3-카르보닐]-아미노}-피페리딘-3-카르복실산 (1-피리미딘-2-일-시클로프로필)-아미드의 결정질 형태

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896170A (en) 1969-02-26 1975-07-22 American Home Prod Intermediates for the preparation of 1,3-dihydro-2h-1, -benzodiazepin-2-ones
IL137720A0 (en) 1998-02-18 2001-10-31 Neurosearch As Compounds and their use as positive ampa receptor modulators
GB9816984D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
WO2002046164A1 (en) 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic compounds
ATE427933T1 (de) * 2002-12-20 2009-04-15 Chemocentryx Inc Inhibitoren der bindungder chemokine i-tac bzw. sdf-1 an den ccxckr2-rezeptor
DE602006018057D1 (de) * 2005-11-10 2010-12-16 Chemocentryx Inc Substituierte chinolone und verwendungsverfahren
US20100331298A1 (en) 2007-12-10 2010-12-30 Cytopathfinder, Inc. Carboxamide Compounds and Their Use
AR091516A1 (es) 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
ES2732437T3 (es) 2014-12-01 2019-11-22 Idorsia Pharmaceuticals Ltd Moduladores del receptor de CXCR7

Also Published As

Publication number Publication date
BR112015030095A2 (pt) 2022-07-12
UA118562C2 (uk) 2019-02-11
PL3004082T3 (pl) 2018-01-31
CA2912133A1 (en) 2014-12-04
HRP20171597T1 (hr) 2017-12-01
US20160107997A1 (en) 2016-04-21
KR20160013197A (ko) 2016-02-03
AU2014272718A1 (en) 2016-01-21
EP3004082A1 (en) 2016-04-13
SG11201509057UA (en) 2015-12-30
CA2912133C (en) 2021-06-22
PH12015502632B1 (en) 2016-03-07
CN105263924B (zh) 2018-10-19
IL242782B (en) 2019-06-30
PT3004082T (pt) 2017-11-13
HK1223353A1 (en) 2017-07-28
TWI640510B (zh) 2018-11-11
US9920010B2 (en) 2018-03-20
AR096490A1 (es) 2016-01-13
NZ715530A (en) 2020-12-18
AU2014272718B2 (en) 2018-06-28
ES2645470T3 (es) 2017-12-05
EA028604B1 (ru) 2017-12-29
HUE036649T2 (hu) 2018-07-30
MY173564A (en) 2020-02-04
WO2014191929A1 (en) 2014-12-04
JP6393749B2 (ja) 2018-09-19
MA38679A1 (fr) 2018-07-31
DK3004082T3 (en) 2017-10-02
IL242782A0 (en) 2016-02-01
KR102302580B1 (ko) 2021-09-15
CL2015003470A1 (es) 2016-06-17
EA201501163A1 (ru) 2016-06-30
SI3004082T1 (sl) 2017-11-30
JP2016520120A (ja) 2016-07-11
CN105263924A (zh) 2016-01-20
CY1119537T1 (el) 2018-03-07
MA38679B1 (fr) 2019-12-31
LT3004082T (lt) 2017-10-25
MX364104B (es) 2019-04-12
NO3004082T3 (https=) 2017-12-30
PH12015502632A1 (en) 2016-03-07
TW201529557A (zh) 2015-08-01
MX2015016429A (es) 2016-03-01
EP3004082B1 (en) 2017-08-02

Similar Documents

Publication Publication Date Title
BR112015030095B1 (pt) Moduladores do receptor de cxcr7
US7414131B2 (en) Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
EP3227263B1 (en) Cxcr7 receptor modulators
WO2017201069A1 (en) Oxoindoline derivatives as protein function modulators
RS55866B1 (sr) Proces za dobijanje derivata piperazinil i diazepanil benzamida
JP2007513181A (ja) 新規m3ムスカリン性アセチルコリン受容体アンタゴニスト
JP4975745B2 (ja) Kspインヒビターとしての置換イミダゾール化合物
EP1658290A2 (en) Compounds and compositions as protein kinase inhibitors
JP7076010B2 (ja) (3s,4s)-1-シクロプロピルメチル-4-{[5-(2,4-ジフルオロ-フェニル)-イソオキサゾール-3-カルボニル]-アミノ}-ピペリジン-3-カルボン酸 (1-ピリミジン-2-イル-シクロプロピル)-アミドの結晶形
KR102838413B1 (ko) 트리아자사이클로도데칸설폰아미드 ("tcd")계 단백질 분비 저해제
HK1223353B (en) Cxcr7 receptor modulators
NZ715530B2 (en) Cxcr7 receptor modulators
HK1232885A1 (en) Compositions of protein receptor tyrosine kinase inhibitors
HK1232885A (en) Compositions of protein receptor tyrosine kinase inhibitors

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ACTELION PHARMACEUTICALS LIMITED (CH)

B25C Requirement related to requested transfer of rights

Owner name: ACTELION PHARMACEUTICALS LIMITED (CH)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/05/2014, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 11A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2829 DE 25-03-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.